Skip to main content

Dr. Kenneth B. Johnson, MD

Hematology & Oncology (Hematology & Oncology Physician)

769 Medical Center Ct, Suite 202
Chula Vista, CA 91911

Who else practices at this address →

San Diego County includes primary care (1% of residents) and mental health (1% of residents) shortage areas. About shortage areas

Call (619) 482-8430

  • Medicare participating

At a glance

Years since graduation
32
In the NPI registry since
2006
Medicare patients seen, 2024
572

Licensed in California since 2002, according to the Medical Board of California. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.

The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is

Education and training

  • 1994Medical school: Georgetown University School of Medicine
  • 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier

Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).

Specialties and state licenses

  • Hematology & Oncology Physician primary
    CA license A79802 (first issued 2002; current)

As reported to the NPI registry. To confirm a license is current, check the state medical board.

Map: Hematology & Oncology per capita by county →

Where they work

Hospitals

Medical groups

Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.

Medicare patients and services

Medicare patients, 2024
572
Services billed
270,264
Patients’ average age
75
Most frequent Medicare services, 2023
ServiceTimesPatients
Injection, ferric carboxymaltose, 1 mg90,75049
Injection, darbepoetin alfa, 1 microgram (non-esrd use)77,10045
Injection, denosumab, 1 mg5,94017
Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count1,654473
Insertion of needle into vein for collection of blood sample1,606476
Established patient office or other outpatient visit, 30-39 minutes993458
Injection, granisetron hydrochloride, 100 mcg62013
Injection of drug or substance under skin or into muscle44675
Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes19247
Administration of chemotherapy into vein, 1 hour or less18127

Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.

Medicare prescriptions

Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.

Payments from drug and device companies

In 2025, 29 companies reported 65 payments worth $1,772 in total to this clinician.

By company
Pfizer Inc.$169
Merck Sharp & Dohme LLC$121
AbbVie Inc.$109
Aveo Pharmaceuticals, Inc.$99.95
E.r. Squibb & Sons, L.l.c.$95.42
Gilead Sciences, Inc.$93.44
Daiichi Sankyo Inc.$86.48
Celgene Corporation$86.10
By type
Food and Beverage$1,672
Education$99.95

What the payments were for

Largest payments other than meals
DateCompanyWhat it was forAmount
Mar 26, 2025Aveo Pharmaceuticals, Inc.
Mar 26, 2025
Education
FOTIVDA · Oncology · in-kind
$99.95

Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.

From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.

Who received the most in California →

Industry-funded research

Named as a principal investigator on 5 industry-funded studies in 2025, from 4 companies. The companies reported $687,840 in research payments for these studies, mostly to the institutions running them.

  • A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma
    Beigene, Ltd. · Active, not recruiting · NCT05100862
  • A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermedi…
    Incyte Corporation
  • A Phase III Randomized Double blind Multicenter Global Study of Rilvegostomig or Pembrolizumab in Combination with Platinum based Chemotherapy for the First line Treatment of Patients with Metastatic Non squamous Non …
    AstraZeneca Pharmaceuticals LP
  • GIREDESTRANT in 1L HER2 ER mBC patients
    Genentech, Inc.
  • A Randomised, Multicentre, Double-Blind, Phase III study will evaluate the safety and efficacy of AZD9833 next generation oral SERD in combination with CDK4 6 inhibitor palbociclib or abemaciclib versus aromatase in…
    AstraZeneca Pharmaceuticals LP

From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.

Other Hematology & Oncology clinicians in Chula Vista

Sources

NPI registry (CMS NPPES, November 2026; record last updated July 19, 2012), Medicare Care Compare, Medicare Physician & Other Practitioners (2024), Medicare Part D Prescribers (2024) and Open Payments (2025). Information is self-reported or billed data and may be out of date; call before visiting.

NPI 1063527711. Official NPI registry record (opens in a new tab). Clinicians can correct their information in NPPES; changes appear here after our next monthly update.